A year after the U.S. Supreme Court’s landmark decision on breast cancer BRCA1 and BRCA2 human DNA patent case that went against the interests of Myriad Genetics, the Australian Federal Court, on September 5, upheld the patents for the mutant BRCA1 human DNA. Products of nature The U.S. Supreme Court had revoked the patent awarded … Continue reading Can BRCA gene be patented?
The Supreme Court has once again ensured that public health overrides commercial interests. The court’s intervention a few days ago brought to an end an eight-year delay in vacating the Bombay High Court’s stay in implementing point of sale rules on tobacco and tobacco products. Though the High Court has to still adjudicate the case, … Continue reading Editorial: Half measure on tobacco control
The U.S. Supreme Court’s landmark ruling that DNA segments are a product of nature and hence not patent-eligible has worldwide significance because it settles the controversial issue of patenting human genes in the one jurisdiction where it has come to matter the most. Though the ruling said that the mere act of isolating genes “is … Continue reading Editorial: BRCA genes – Patent justice
Awareness about genetic testing to know if a woman with a family history of breast cancer and ovarian cancer carries certain deleterious mutations in the BRCA1 and BRCA2 genes has surely increased following Angelina Jolie’s recent revelation of her bilateral mastectomy. In the process, she has turned the spotlight on a high-voltage patent case in … Continue reading Editorial: When commerce rules the roost
The U.S. Supreme Court is currently hearing a case on the validity of the isolated DNA and cDNA patents filed on BRCA1 and BRCA2 human genes used for diagnosing breast and ovarian cancers. The Association for Molecular Pathology has petitioned the Supreme Court to invalidate the patents held jointly by the Utah-based Myriad Genetics and … Continue reading BRCA gene case: will the court take the middle ground?
Published in The Hindu on February 10, 2012 With the Supreme Court issuing notice to the Central government on the matter of illegal drug trials, the sordid state of human clinical trials is all set to be exposed. For multinational companies eager to cut corners, India offers an attractive package of weak laws, lax and … Continue reading Editorial: Clinical trials in the dock